Solasia Pharma K.K. revised consolidated financial guidance for the fiscal year ending December 31, 2022. For the year, the company expects revenue of ¥1,150 million, operating loss of ¥2,350 million, loss attributable to owners of parent of ¥2,450 and basic loss per share of ¥14.60 compared to previous guidance of revenue of ¥1,150 million, operating loss of ¥2,150 million, loss attributable to owners of parent of ¥2,250 and basic loss per share of ¥13.41.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
27 JPY | 0.00% | +3.85% | -40.00% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-40.00% | 31.53M | |
-1.67% | 89.08B | |
+2.76% | 40.9B | |
-12.92% | 32.25B | |
+54.69% | 25.14B | |
-16.51% | 15.39B | |
-8.27% | 11.91B | |
-42.60% | 11.89B | |
-12.82% | 11.64B | |
+7.34% | 9.03B |
- Stock Market
- Equities
- 4597 Stock
- News Solasia Pharma K.K.
- Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022